Success Metrics

Clinical Success Rate
78.4%

Based on 29 completed trials

Completion Rate
78%(29/37)
Active Trials
5(11%)
Results Posted
110%(32 trials)
Terminated
8(18%)

Phase Distribution

Ph phase_2
28
64%
Ph phase_3
1
2%
Ph not_applicable
3
7%
Ph phase_1
12
27%

Phase Distribution

12

Early Stage

28

Mid Stage

1

Late Stage

Phase Distribution44 total trials
Phase 1Safety & dosage
12(27.3%)
Phase 2Efficacy & side effects
28(63.6%)
Phase 3Large-scale testing
1(2.3%)
N/ANon-phased studies
3(6.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

74.4%

29 of 39 finished

Non-Completion Rate

25.6%

10 ended early

Currently Active

5

trials recruiting

Total Trials

44

all time

Status Distribution
Active(5)
Completed(29)
Terminated(10)

Detailed Status

Completed29
Terminated8
Active, not recruiting5
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
44
Active
5
Success Rate
78.4%
Most Advanced
Phase 3

Trials by Phase

Phase 112 (27.3%)
Phase 228 (63.6%)
Phase 31 (2.3%)
N/A3 (6.8%)

Trials by Status

active_not_recruiting511%
terminated818%
completed2966%
withdrawn25%

Recent Activity

5 active trials
Showing 5 of 44
active_not_recruitingphase_2

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

NCT01841736
active_not_recruitingphase_2

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

NCT02180867
active_not_recruitingphase_3

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

NCT01575548
active_not_recruitingphase_1

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

NCT01552356
active_not_recruitingphase_1

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

NCT01684397
View all 44 trials

Clinical Trials (44)

Showing 20 of 44 trialsScroll for more
NCT01841736Phase 2

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Active Not Recruiting
NCT02180867Phase 2

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Active Not Recruiting
NCT01575548Phase 3

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

Active Not Recruiting
NCT01552356Phase 1

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

Active Not Recruiting
NCT01684397Phase 1

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Active Not Recruiting
NCT01436227Phase 2

Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

Completed
NCT03660930Phase 1

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

Terminated
NCT01767636Phase 2

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Completed
NCT01402271Phase 1

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed
NCT02601209Phase 1

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Terminated
NCT01462630Phase 2

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Completed
NCT01236547Phase 2

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

Completed
NCT01157091Phase 2

Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

Completed
NCT01664182Phase 2

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Completed
NCT02357810Phase 2

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Completed
NCT03334409Phase 2

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Terminated
NCT01532687Phase 2

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

Completed
NCT01465659Phase 1

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Completed
NCT01446809Not Applicable

Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

Completed
NCT00454363Phase 2

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Completed

Drug Details

Intervention Type
DRUG
Total Trials
44